Recorded an impairment loss on intangible assets of 16.4 billion yen and a special loss of 74.8 billion yen related to valuation loss on affiliate shares in FY2025 Q4. The impact on consolidated financial results is limited.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4503","jir_company_name":"Astellas Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-27","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4503-20260427-05.pdf","jir_short_summary":"Recorded an impairment loss on intangible assets of 16.4 billion yen and a special loss of 74.8 billion yen related to valuation loss on affiliate shares in FY2025 Q4. The impact on consolidated financial results is limited.","jir_summary":"### Regarding the Impairment Loss on Intangible Assets\nAstellas Pharma, in relation to the gene therapy drug resamirigene bilparvovec (AT132) under development for patients with X-linked myotubular myopathy, has reviewed the value of AT132-related intangible assets due to the strategic discontinuation of the program and reallocation of resources to the next-generation gene therapy ASP2957. As a result, an impairment loss of 16.4 billion yen was recorded under other expenses in the FY2025 Q4 financial statements.\n\n### Recognition of Special Loss and Impact on Consolidated Financial Statements\nRegarding shares of affiliate companies, the carrying amount of shares in the subsidiary Ogeda B.V. fell below its net realizable value, leading to a valuation loss on affiliate shares of 74.8 billion yen recognized as a special loss in the individual financial statements. This valuation loss is eliminated in the consolidated financial statements and therefore has no impact on consolidated earnings.","jir_financial_highlights":"Impairment Loss on Intangible Assets: 16.4 billion yen (Unknown)\nValuation Loss on Affiliate Shares (Special Loss): 74.8 billion yen (Unknown)\nImpact on Consolidated Profit and Loss: None (Eliminated) (Unknown)","jir_category":"","jir_hashtags":"#AstellasPharma, #FinancialSummary, #ImpairmentLoss, #SpecialLoss, #JapaneseStocks","jir_key_figures":"Impairment Loss on Intangible Assets: 16.4 billion yen (FY2025 Q4)\nValuation Loss on Affiliate Shares: 74.8 billion yen (Special Loss in Individual Financial Statements)\nImpact on Consolidated Profit and Loss: None (Eliminated)","jir_meta_title":"[Astellas Pharma] FY2025 Q4 Financial Results\uff5cRecorded 16.4 Billion Yen Impairment Loss on Intangible Assets","jir_meta_description":"Astellas Pharma recorded a 16.4 billion yen impairment loss on the intangible assets of gene therapy drug AT132 and a 74.8 billion yen valuation loss on affiliate shares as special losses in the FY2025 Q4 financial results. There is no impact on consolidated earnings.","jir_og_title":"[Astellas Pharma] FY2025 Q4 Financial Results\uff5cRecorded 16.4 Billion Yen Impairment Loss on Intangible Assets","jir_og_description":"Astellas Pharma recognized an impairment loss of 16.4 billion yen on intangible assets and special losses of 74.8 billion yen in FY2025 Q4. The impact on consolidated financial statements is limited.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6911,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-42900","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n